MT Newswires
Vanda Pharmaceuticals Submits Biologics License Application to US FDA for Generalized Pustular Psoriasis Drug
➖
AI Sentiment
Neutral
5/10
Vanda Pharmaceuticals Inc. News
Latest updates and market news for VNDA
3 news
Dec 11 - Dec 17, 2025
Page 1
PR Newswire
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
📈
AI Sentiment
Highly Positive
9/10
PR Newswire
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
➖
AI Sentiment
Neutral
5/10
Share this news page